Edwards J C W, Leandro M J, Cambridge G
Centre for Rheumatology, University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK.
Biochem Soc Trans. 2002 Aug;30(4):824-8. doi: 10.1042/bst0300824.
B-lymphocyte depletion therapy is being explored in a wide range of autoimmune disorders. In many, there is early evidence for efficacy, and immunosuppression has not been a major problem. The mechanism of action is unclear, but appears to be consistent with the lowering of autoantibody levels, where relevant antibodies are quantifiable. An interesting finding is the persistence of clinical improvement for periods of 1 year or more after B-lymphocyte return, which supports the concept that stochastic generation of rare pathogenic B-lymphocyte subsets may be a rate-limiting step in pathogenesis.
B淋巴细胞清除疗法正在多种自身免疫性疾病中进行探索。在许多疾病中，早期就有疗效证据，且免疫抑制并非主要问题。其作用机制尚不清楚，但似乎与自身抗体水平降低一致，在相关抗体可定量的情况下。一个有趣的发现是，B淋巴细胞恢复后临床改善可持续1年或更长时间，这支持了一个概念，即罕见致病性B淋巴细胞亚群的随机产生可能是发病机制中的一个限速步骤。
